Jefferies analyst Akash Tewari upgraded Regeneron Pharmaceuticals to Buy from Hold with a price target of $925, up from $675.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on REGN:
- Regeneron May Win Big with New Drug
- Raymond James ups Regeneron to Market Perform as few downside catalysts remain
- Regeneron upgraded to Market Perform from Underperform at Raymond James
- Regeneron, Sanofi report Dupixent trial meets primary and secondary endpoints
- Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial